Semaglutide

A GLP-1 receptor agonist originally developed for type 2 diabetes that has become the leading FDA-approved medication for chronic weight management. Semaglutide mimics the incretin hormone GLP-1, reducing appetite, slowing gastric emptying, and improving glycemic control.

• Activates GLP-1 receptors in the hypothalamus to reduce appetite
• Delays gastric emptying to promote satiety
• Enhances glucose-dependent insulin secretion from pancreatic beta cells
• Suppresses glucagon release to improve blood sugar regulation

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2 (MEN2)
• History of pancreatitis
• Severe gastrointestinal disease

Store unused pens at 2–8°C (36–46°F). In-use pens can be kept at room temperature (up to 30°C (86°F)) for up to 6 weeks.

The STEP clinical trial program demonstrated that semaglutide 2.4 mg weekly produces an average weight loss of approximately 15% of body weight over 68 weeks. The SELECT trial further showed a 20% reduction in major adverse cardiovascular events. FDA-approved for chronic weight management in adults with BMI ≥30 or ≥27 with at least one weight-related comorbidity.